Comorbidity Profiles among Obese–Diabetic End-Stage Renal Disease Patients: Data from REIN Registry of PACA Region of France

Kakar, Akshay; Mouelhi, Yosra; Loundou, Anderson; Crémades, Adeline; Gentile, Stéphanie

doi:10.2147/dmso.s291343

Cited by 1 publication

(1 citation statement)

References 32 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with end-stage kidney disease are at high cardiovascular risk due to the underlying causes of their renal failure, such as hypertension and diabetes, as well as independent risk factors like hyperlipidemia, smoking, and obesity. 1 –4 Although renal transplantation is considered the optimal treatment for end-stage kidney disease and may lessen cardiovascular risk when compared to dialysis, preexisting disease may still impact outcomes. 5 Following transplant, recipients often remain at increased cardiovascular risk as immunosuppression and posttransplant complications such as anemia and acute rejection can heighten existing risk factors.…”

Section: Introductionmentioning

confidence: 99%

The Impact of Atherosclerotic Cardiovascular Risk on Graft Failure in Deceased-Donor Renal Transplantation

et al. 2021

View full text Add to dashboard Cite

Introduction: Pretransplant cardiovascular risk may be amplified after renal transplant, but little is known about its impact on graft outcomes. Research question: The purpose of this study was to determine if pretransplant cardiovascular risk was associated with graft outcomes. Design: This retrospective study included deceased-donor renal transplant recipients from 2010-2015. Atherosclerotic cardiovascular disease risk for patients without prior disease was calculated and patients were categorized into high (score >20%), intermediate (7.5-20%), and low risk (<7.5%). Patients with and without prior cardiovascular disease were also compared. The main endpoint was graft failure at 3-years post-transplant. Other outcomes included major adverse cardiovascular events, biopsy-proven rejection, and mortality. Results: In patients without prior atherosclerotic cardiovascular disease (N = 115), graft failure rates (4.5% vs 11.3% vs 12.5%; ( P = 0.64) and major adverse cardiovascular events (9.1% vs 13.2% vs 5.0%; P = 0.52) were similar in the high, intermediate, and low risk groups. In those with prior disease (N = 220), rates of primary nonfunction (6.8% vs 1.7%; P = 0.04), major adverse cardiovascular events (7.3% vs 2.6%; P = 0.01), and heart failure (10.9% vs 3.5%; P = 0.02) were higher than those without cardiovascular; rates of major adverse cardiovascular events and heart failure were insignificant after adjusting for age, gender, and race. Other outcomes were not different. Outcomes did not differ based on pretransplant cardiovascular risk. Discussion: Pretransplant atherosclerotic cardiovascular disease was associated with increased early graft failure but similar outcomes at 3-years, suggesting cardiac risk alone should not exclude transplantation.

show abstract